Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer
Journal of Korean Medical Science
;
: e178-2018.
Article
in English
| WPRIM
| ID: wpr-715018
ABSTRACT
BACKGROUND:
Lung cancer is the most common cause of cancer-related mortality worldwide. We previously reported the identification of a new genetic marker, cellular retinoic acid binding protein 2 (CRABP2), in lung cancer tissues. The aim of this study was to assess plasma levels of CRABP2 from patients with non-small cell lung cancer (NSCLC).METHODS:
Blood samples that were collected from 122 patients with NSCLC between September 2009 and September 2013 were selected for the analysis, along with samples from age- (± 5 years), sex-, and cigarette smoking history (± 10 pack-years [PY])-matched controls from the Korea Biobank Network. The control specimens were from patients who were without malignancies or pulmonary diseases. We measured plasma levels of CRABP2 using commercially available enzyme-linked immunosorbent assay kits.RESULTS:
The mean age of the NSCLC patients was 71.8 ± 8.9 years, and the median cigarette smoking history was 32 PY (range, 0–150 PY). Plasma CRABP2 levels were significantly higher in patients with NSCLC than in the matched controls (37.63 ± 28.71 ng/mL vs. 24.09 ± 21.09 ng/mL, P < 0.001). Higher plasma CRABP2 levels were also correlated with lower survival rates in NSCLC patients (P = 0.014).CONCLUSION:
Plasma CRABP2 levels might be a novel diagnostic and prognostic marker in NSCLC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasma
/
Tretinoin
/
Enzyme-Linked Immunosorbent Assay
/
Biomarkers
/
Smoking
/
Carrier Proteins
/
Genetic Markers
/
Survival Rate
/
Mortality
/
Carcinoma, Non-Small-Cell Lung
Type of study:
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS